Literature DB >> 20798006

Is potroom asthma due more to sulphur dioxide than fluoride? An inception cohort study in the Australian aluminium industry.

Michael John Abramson1, Geza Paul Benke, Jisheng Cui, Nicholas Hubert de Klerk, Anthony Del Monaco, Martine Dennekamp, Lin Fritschi, Arthur William Musk, Malcolm Ross Sim.   

Abstract

OBJECTIVES: Although an asthma-like syndrome has been recognised in aluminium smelter workers for over 70 years, the causal agent has been difficult to identify.
METHODS: An inception cohort study was conducted at two Australian aluminium smelters where 446 employees participated over a period of 9 years. Cumulative exposures between interviews were estimated from job histories using a task exposure matrix based on measurements in the smelters. Participants completed an MRC respiratory questionnaire, spirometry and methacholine challenge test. Data were analysed with generalised estimating equations to allow for repeated measurements of each participant.
RESULTS: Wheeze and chest tightness, the two symptoms most closely related to asthma, showed associations with occupational exposures. SO(2) exposure was significantly associated with these symptoms, bronchial hyper-responsiveness (BHR) to methacholine (a feature of asthma), airflow limitation (reduced forced expiratory volume in 1 second/forced vital capacity ratio) and longitudinal decline in lung function. Fluoride exposure was associated with the same outcomes, but less strongly. Inhalable dust and the benzene soluble fraction (BSF) were associated with symptoms of asthma and BHR. Although many of the exposures were highly correlated, further modelling suggested that of the known respiratory irritants, SO(2) was more likely than fluoride to be primarily responsible for the symptoms observed. Fluoride, inhalable dust and SO(2) were the most important airborne contaminants associated with effects on lung function.
CONCLUSIONS: The observed effects were detected at contaminant levels within occupational exposure standards, so further reductions are required, particularly in SO(2) exposures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20798006     DOI: 10.1136/oem.2009.046458

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  7 in total

1.  Accelerated lung function decline in an aluminium manufacturing industry cohort exposed to PM2.5: an application of the parametric g-formula.

Authors:  Andreas M Neophytou; Sadie Costello; Sally Picciotto; Elizabeth M Noth; Sa Liu; Liza Lutzker; John R Balmes; Katharine Hammond; Mark R Cullen; Ellen A Eisen
Journal:  Occup Environ Med       Date:  2019-10-14       Impact factor: 4.402

Review 2.  Pulmonary fluorosis: a review.

Authors:  Jaishabanu Ameeramja; Ekambaram Perumal
Journal:  Environ Sci Pollut Res Int       Date:  2017-08-25       Impact factor: 4.223

3.  Construction of a Job Exposure Matrix to Dust, Fluoride, and Polycyclic Aromatic Hydrocarbons in the Norwegian Aluminum Industry using Prediction Models.

Authors:  Vidar Søyseth; Paul Henneberger; Mohammed Abbas Virji; Berit Bakke; Johny Kongerud
Journal:  Ann Occup Hyg       Date:  2015-09-25

4.  Annual decline in forced expiratory volume is steeper in aluminum potroom workers than in workers without exposure to potroom fumes.

Authors:  Vidar Søyseth; Paul K Henneberger; Gunnar Einvik; Mohammed Abbas Virji; Berit Bakke; Johny Kongerud
Journal:  Am J Ind Med       Date:  2016-02-08       Impact factor: 2.214

Review 5.  Respiratory disorders in aluminum smelter workers.

Authors:  Johny Kongerud; Vidar Søyseth
Journal:  J Occup Environ Med       Date:  2014-05       Impact factor: 2.162

Review 6.  Community health risk assessment of primary aluminum smelter emissions.

Authors:  Stephen Claude Martin; Claude Larivière
Journal:  J Occup Environ Med       Date:  2014-05       Impact factor: 2.162

Review 7.  Diffuse parenchymal diseases associated with aluminum use and primary aluminum production.

Authors:  Oyebode A Taiwo
Journal:  J Occup Environ Med       Date:  2014-05       Impact factor: 2.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.